

Subject: RE: Next draft of TAGFA
From: Richard Bazinet <richard.bazinet@utoronto.ca>
Date: 2017-03-13 08:26 AM
To: Luke Johnston <luke.johnston@mail.utoronto.ca>, Anthony Hanley <anthony.hanley@utoronto.ca>

Luke,
Looks good. A few things we could consider.

1- The title could be more positive, giving the main result. Fatty acid markers of de novo lipogenesis are associated with ... This is always a balance between being conservative and flashy. Worth thinking about.

2- In figure 7. 18:1n-9 and 18:1n-7 seem to group together as well as 20:5n-3 and 22:6n-3. Is there anything to this? Worth a comment?

3- Take a stab at the abstract.

4. Most of those journals seem reasonable to me. JCI is a bit of basic experimental medicine.

-----Original Message-----

From: Luke Johnston [<mailto:luke.johnston@mail.utoronto.ca>]
Sent: March 13, 2017 1:12 AM
To: Anthony Hanley <anthony.hanley@utoronto.ca>; Richard Bazinet <richard.bazinet@utoronto.ca>
Subject: Next draft of TAGFA

Hey Tony and Richard,

I've added Richard's suggestions re: the DNL TAGFA and total clinical TAG to the manuscript.

I also finished up running the analysis looking at simple associations with incidence of dysglycemia. There were no associations with TAGFA or the PLS comp with incident dysglycemia. Clinical TAG did have an association, though modest. I haven't included the analysis as an attachment, though if either of you are interested I can send it along.

As for possible journal, do either of you have any suggestions? Seems like the studies tended to be published in Diabetes, Diabetes Care, Diabetologia, JCEM, or JCI. Thoughts?

Tony, should I send out the manuscript to other co-authors or after another revision? Or when we've made a decision on the journal?

Luke

--

Luke W. Johnston, MSc, PhD(c)

Department of Nutritional Sciences
Faculty of Medicine, University of Toronto FitzGerald Building, 150 College Street, Room 316 Toronto, ON, Canada M5S 3E2
T: (416) 978-4152